Novo Nordisk (NYSE: NVO) reported Q3 EPS of DKK5.00. Revenue for the quarter came in at DKK58.73 billion.

GUIDANCE

Outlook: Sales growth of 32% to 38% (prior 27% to 33%); Financial items (net) of Gain of around DKK 1.6 billion; Effective tax rate of 19% to 21%; Capital expenditure is still expected to be around DKK 25 billion in 2023; The free cash flow is now expected to be DKK 65-73 billion reflecting the sales growth; Operating profit growth is now expected to be 40% to 46% at CER.

For earnings history and earnings-related data on Novo Nordisk (NVO) click here.